Drug Trial Radar · NCT02637687
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Last checked: Nov 20, 2026Latest source record: Jun 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
154
Actual
Start
Dec 16, 2015
Primary completion
Jul 20, 2024
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Dec 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.
Conditions
- Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)Drug
BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of participants in an assigned dose cohort with treatment emergent adverse events (TEAEs) by grade assessed by NCI-CTCAE v 4.03 who experience a DLTTime frame: From Day 1 to Day 28 of Cycle 1 (1 Cycle=28 days)
- Phase 1: Number of participants with TEAEsTime frame: From first dose of larotrectinib up to 93 months
- Phase 1: Severity of TEAEsTime frame: From first dose of larotrectinib up to 93 months
- Phase 2: Overall response rate (ORR) by IRRCTime frame: From first dose of Larotrectinib to disease progression or subsequent therapy or surgical intervention or death, up to 76 months
Locations
45 sites in 21 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles - Hematology/Oncology
Los Angeles, California
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California
Lucille Packard Children's Hospital Stanford - Pediatric Nephrology
Palo Alto, California
Nemours Children's Hospital - Florida - Hematology / Oncology
Orlando, Florida
Dana-Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center New York - Main Campus
New York, New York
Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension
Cincinnati, Ohio
Children's Hospital of Philadelphia - Hematology/Oncology
Philadelphia, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Seattle Children's Hosptial - Oncology
Seattle, Washington
Sydney Children's Hospital
Sydney, New South Wales, Australia
Women's and Children's Hospital
North Adelaide, South Australia, Australia
Royal Children's Hospital Melbourne
Parkville, Victoria, Australia
BC Children's Hospital - Hematology/Oncology
Vancouver, British Columbia, Canada
The Hospital for Sick Children (SickKids)
Toronto, Ontario, Canada
CHU Sainte-Justine
Montreal, Quebec, Canada
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
FN Brno - Detska nemocnice
Brno, Czechia
Fakultni nemocnice v Motole
Prague, Czechia
Rigshospitalet - Børn og Unge
Copenhagen, Denmark
Institut Curie - Ulm - Paris
Paris, France
Gustave Roussy - Departement Oncologie-Radiotherapie
Villejuif, France
Charité - Campus Virchow-Klinikum (CVK), Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
Berlin, Germany
Universitaetsklinikum Heidelberg - KiTZ | Klinik für Paediatrische Onkologie, Haematologie, Immunologie und Pneumologie
Heidelberg, Baden-Wurttemberg, Germany
KLINIKUM STUTTGART - Olgahospital | Paediatrie 5 (Onkologie, Haematologie, Immunologie)
Stuttgart, Baden-Wurttemberg, Germany
Children's Health Ireland Crumlin
Crumlin, Dublin, Ireland
Clalit Health Services Schneider Children's Medical Center
Petah Tikva, Israel
Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Pediatria Oncologica
Milan, Lombardy, Italy
Kyushu University Hospital
Fukuoka, Japan
Kanagawa Children's Medical Center
Yokohama, Kanagawa, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Prinses Maxima Centrum
Utrecht, Netherlands
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Severance Hospital, Yonsei University Health System
Seoul, Seoul Teugbyeolsi, South Korea
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea
Ciutat Sanitaria i Universitaria de la Vall d'Hebron
Barcelona, Spain
Karolinska Universitetssjukhuset i Solna
Stockholm, Sweden
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.